Daklinza 30 mg film-coated tablets European Union - English - myHealthbox

daklinza 30 mg film-coated tablets

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - film-coated tablet (tablet) - 30 mg - hepatitis c, chronic - direct-acting antiviral - indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults

Daklinza 60 mg film-coated tablets European Union - English - myHealthbox

daklinza 60 mg film-coated tablets

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - film-coated tablet (tablet) - 60 mg - hepatitis c, chronic - direct-acting antiviral - indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults

OPDIVO 10 mg/mL concentrate for solution for infusion United Kingdom - English - myHealthbox

opdivo 10 mg/ml concentrate for solution for infusion

bristol-myers squibb pharma eeig - nivolumab - concentrate for solution for infusion - 10 mg/ml - antineoplastic agents, monoclonal antibodies - as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults

Yervoy New Zealand - English - Medsafe (Medicines Safety Authority)

yervoy

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 200 mg/40 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

Yervoy New Zealand - English - Medsafe (Medicines Safety Authority)

yervoy

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 50 mg/10 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

REYATAZ 200 MG Israel - English - Ministry of Health

reyataz 200 mg

bristol - myers squibb, israel - atazanavir as sulfate - capsules - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

BARACLUDE 0.5 MG Israel - English - Ministry of Health

baraclude 0.5 mg

bristol - myers squibb, israel - entecavir; entecavir - film coated tablets - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease. baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease.

Lipostat 20mg tablets United Kingdom - English - myHealthbox

lipostat 20mg tablets

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 20 mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet: reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation

Lipostat 40mg tablets United Kingdom - English - myHealthbox

lipostat 40mg tablets

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 40mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.

Lipostat 10mg tablets United Kingdom - English - myHealthbox

lipostat 10mg tablets

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 10mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.